Itopride HCI
Phase 3Small molecule
Itopride HCI is one of 18 small molecule programs targeting Gastroparesis. It is currently in Phase 3.
1
Indications
3
Total Trials
2
Active Trials
17
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
20 competitors in Gastroparesis
#DrugCompanyPhaseTrials
1Cialis
Eli LillyApproved
Haldol
DDePuy Orthopaedics
Approved
Prilosec
DDexcel Pharma Technologies Ltd.
Approved
Pitocin
RRetrophin
Approved
Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Kytril
CConrado Roberto Hoffmann Filho
Approved
Relistor
SSalix
Approved
Nereus
VVanda Pharmaceuticals
Phase 3
Propulsid
WWim Janssens
Approved
Zelnorm
AAlfasigma S.p.A.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Efficacy1 trial
Efficacy of Itopride Versus Metoclopramide in Hospitalized Medicine Patients With High Gastric Residual Volume
Not yet recruiting·—·Phase 4·NCT07031479·86 enrolled
Irritable Bowel Syndrome1 trial
Gastroparesis1 trial
Effect of Itopride on Semaglutide Gastroparesis
Recruiting·—·Phase 4·NCT07254715·60 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Itopride HCI. EMBL-EBI & Wellcome Sanger Institute.
- [4]